Adaptive Biotechnologies Appoints Seasoned Biotechnology Executives Kevin Conroy and Michelle Griffin to Board of Directors

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies today announced Kevin Conroy, chairman and CEO
of Exact Sciences Corporation, and Michelle Griffin, director at Acer
Therapeutics, Inc. and HTG Molecular Diagnostics, Inc., have been
elected to the board of directors. Board member Arnold J. Levine, PhD,
has transitioned to Adaptive’s scientific advisory board.

Mr. Conroy brings extensive business, legal, and executive leadership
experience in the biotechnology and molecular diagnostics industries. As
chief executive officer of Exact Sciences Corporation, he has most
recently overseen the FDA approval, launch, and commercialization of
Cologuard®, the first non-invasive, stool-based DNA screening
test approved for detecting colorectal cancer. Ms. Griffin brings
extensive operational experience in the biotechnology industry and deep
corporate finance experience, conducting many public financings,
including the initial public offerings for Trubion Pharmaceuticals, Inc.
and Corixa Corporation later acquired by GSK. Their collective board and
executive leadership experience in the biotechnology industry will
benefit Adaptive as the company accelerates the development and
commercialization of diagnostic and therapeutic product opportunities
derived from its immune medicine platform.

Kevin and Michelle are recognized, seasoned leaders in the
biotechnology industries, and we will benefit tremendously from their
knowledge as Adaptive continues to grow as a commercial stage
biotechnology company,” said Chad Robins, CEO and co-founder of Adaptive
Biotechnologies. “Kevin and Michelle collectively bring deep experience
in the development and commercialization of molecular diagnostics and
therapeutics, and we look forward to their direction and support as
Adaptive continues to advance our clinical pipeline based on our
proprietary immune medicine platform. We also want to thank Arnie Levine
for his 8 years of service on our board of directors and for his
continued support serving on our scientific advisory board.”

Mr. Conroy has served as the president, chief executive officer and
chairman of the board of directors of Exact Sciences Corporation, a
public molecular diagnostic company, since March 2009. He also serves on
the board of directors of Epizyme, Inc., a public clinical-stage
biopharmaceutical company, and Arya Sciences Acquisition Corp., a public
special purpose acquisition company sponsored by an affiliate of
Perceptive Advisors LLC. Prior to joining Exact Sciences Corporation,
Mr. Conroy served as president and chief executive officer of Third Wave
Technologies, Inc., a molecular diagnostics company, from 2005 to 2008.
Mr. Conroy holds a JD from the University of Michigan Law School and a
BS in Electrical Engineering from Michigan State University.

Adaptive Biotechnologies is writing the next chapter in precision
medicine, an area that is increasingly critical to improving health
outcomes and a place where diagnostics are playing a significant role,”
said Mr. Conroy. “I am excited to join this board and support the
leadership team to design truly personalized diagnostics for patients
battling cancer and other diseases.”

Ms. Griffin currently serves as a member of the board of directors and
chair of the audit committee for public companies Acer Therapeutics,
Inc., a clinical-stage biopharmaceutical company, and HTG Molecular
Diagnostics, Inc. Ms. Griffin previously served on the board of
directors and as chair of the audit committee for public companies
PhaseRx, Inc., from 2016 to 2018; OncoGenex Pharmaceuticals Inc., from
2008 to 2011 and Sonus Pharmaceuticals, Inc., from 2004 to 2008. Ms.
Griffin served as executive vice president, Operations, and chief
financial officer at OncoGenex Pharmaceuticals, Inc. from 2011 to 2013,
served as acting chief executive, senior vice president and chief
operating officer at Trubion Pharmaceuticals, Inc. from 2009 until its
acquisition in 2010 and as its chief financial officer from 2006 to
2009; and served as senior vice president and chief financial officer of
Dendreon Corp. from 2005 to 2006. Ms. Griffin holds a BS in marketing
from George Mason University and an MBA from Seattle University.

Adaptive is decoding the adaptive immune system and leveraging this
information to help discover personalized cellular therapies with the
goal of helping to change how disease is treated,” said Ms. Griffin,
director at Acer Therapeutics, Inc. and HTG Molecular Diagnostics, Inc.
I’m thrilled to join the board to support Adaptive’s leadership as they
continue to harness the power of the immune system to help patients
fight disease.”

About Adaptive Biotechnologies

Adaptive Biotechnologies is a pioneer and leader in immune-driven
medicine that aims to improve people’s lives by learning from the wisdom
of their adaptive immune systems. Adaptive’s proprietary immune medicine
platform reveals and translates insights from our adaptive immune
systems with unprecedented scale and precision. Working with drug
developers, clinicians and academic researchers, we are applying these
insights to develop products that will transform the way diseases such
as cancer, autoimmune conditions, and infectious diseases are diagnosed
and treated. For more information, please visit


Adaptive Biotechnologies
Beth Keshishian
Director, Corporate

error: Content is protected !!